PE20211978A1 - Compuesto heterociclo pentaciclico - Google Patents

Compuesto heterociclo pentaciclico

Info

Publication number
PE20211978A1
PE20211978A1 PE2021001331A PE2021001331A PE20211978A1 PE 20211978 A1 PE20211978 A1 PE 20211978A1 PE 2021001331 A PE2021001331 A PE 2021001331A PE 2021001331 A PE2021001331 A PE 2021001331A PE 20211978 A1 PE20211978 A1 PE 20211978A1
Authority
PE
Peru
Prior art keywords
pentaciclic
dysfunction
cholinergic neurons
disease
heterocycle compound
Prior art date
Application number
PE2021001331A
Other languages
English (en)
Inventor
Yoshiaki Ohashi
Yoshihiko Norimine
Tamaki HOSHIKAWA
Yu Yoshida
Yoshihisa Kobayashi
Nobuhiro Sato
Koji Hagiwara
Nobuaki Sato
Shinsuke Hirota
Takaaki Harada
Hikaru YOSHIMURA
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20211978A1 publication Critical patent/PE20211978A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos representados por las formulas (I) a (XVII) o sales farmaceuticamente aceptables de estos tienen un efecto de activacion de las neuronas colinergicas y tienen un uso potencial de un agente terapeutico para la disfuncion cognitiva. Tambien se emplean en el tratamiento de enfermedades para las que se ha indicado que hay una asociacion entre el descenso de la funcion cognitiva y la disfuncion de las neuronas colinergicas incluyen la Corea de Huntington, sindrome de Down, esclerosis lateral amiotrofica (ELA), enfermedad de Parkinson, depresion mayor, esquizofrenia y similares.
PE2021001331A 2019-03-05 2020-03-03 Compuesto heterociclo pentaciclico PE20211978A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019039351 2019-03-05
PCT/JP2020/008881 WO2020179780A1 (ja) 2019-03-05 2020-03-03 五環式複素環化合物

Publications (1)

Publication Number Publication Date
PE20211978A1 true PE20211978A1 (es) 2021-10-05

Family

ID=72336168

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001331A PE20211978A1 (es) 2019-03-05 2020-03-03 Compuesto heterociclo pentaciclico

Country Status (21)

Country Link
US (1) US11358972B2 (es)
EP (1) EP3936190A4 (es)
JP (1) JP7504864B2 (es)
KR (1) KR20210135224A (es)
CN (1) CN113453762B (es)
AR (1) AR118235A1 (es)
AU (1) AU2020232044A1 (es)
BR (1) BR112021015975A2 (es)
CA (1) CA3129861A1 (es)
CL (1) CL2021002144A1 (es)
CO (1) CO2021010512A2 (es)
EA (1) EA202191966A1 (es)
IL (1) IL285511B2 (es)
JO (1) JOP20210219A1 (es)
MA (1) MA55221A (es)
MX (1) MX2021009685A (es)
PE (1) PE20211978A1 (es)
SG (1) SG11202108780PA (es)
TW (1) TWI821537B (es)
WO (1) WO2020179780A1 (es)
ZA (1) ZA202105729B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020233452A1 (en) 2019-03-05 2021-09-02 Eisai R&D Management Co., Ltd. Salt of pentacyclic compound and crystals thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE258234C (es)
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (es) 1990-02-08 1993-01-01 Pfizer
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5736992A (en) * 1994-10-31 1998-04-07 Hewlett-Packard Pressure regulated free-ink ink-jet pen
KR100203456B1 (ko) 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
DE10246207B4 (de) * 2002-10-04 2008-04-03 Disetronic Licensing Ag Mikrodialysesonde mit spiralförmiger Leitung
US8252520B2 (en) * 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
MX2007004640A (es) 2004-10-20 2007-06-08 Hoffmann La Roche Derivados de benzodiazepina sustituidos con halogeno.
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
GB201100181D0 (en) * 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
JP6531093B2 (ja) * 2014-05-16 2019-06-12 武田薬品工業株式会社 含窒素複素環化合物
AR112788A1 (es) 2017-09-07 2019-12-11 Eisai R&D Man Co Ltd Compuesto pentacíclico
AU2020233452A1 (en) 2019-03-05 2021-09-02 Eisai R&D Management Co., Ltd. Salt of pentacyclic compound and crystals thereof

Also Published As

Publication number Publication date
CL2021002144A1 (es) 2022-02-04
SG11202108780PA (en) 2021-09-29
JP7504864B2 (ja) 2024-06-24
EA202191966A1 (ru) 2021-12-08
US20200283452A1 (en) 2020-09-10
EP3936190A1 (en) 2022-01-12
MA55221A (fr) 2022-01-12
IL285511A (en) 2021-09-30
WO2020179780A1 (ja) 2020-09-10
AR118235A1 (es) 2021-09-22
TW202100528A (zh) 2021-01-01
KR20210135224A (ko) 2021-11-12
CA3129861A1 (en) 2020-09-10
JOP20210219A1 (ar) 2023-01-30
JPWO2020179780A1 (es) 2020-09-10
ZA202105729B (en) 2022-08-31
AU2020232044A1 (en) 2021-09-02
CO2021010512A2 (es) 2021-10-29
CN113453762A (zh) 2021-09-28
IL285511B1 (en) 2024-06-01
BR112021015975A2 (pt) 2021-10-05
MX2021009685A (es) 2021-09-10
US11358972B2 (en) 2022-06-14
CN113453762B (zh) 2024-06-07
EP3936190A4 (en) 2022-11-16
TWI821537B (zh) 2023-11-11
IL285511B2 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
AR053026A1 (es) Composiciones de anticuerpos anti factor de estimulacion de colonias de macrofagos (anti-m csf)
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
MA56547A (fr) Formulations d'agents pénétrants transdermiques contenant du cannabidiol
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
BRPI0809655B8 (pt) uso de um composto e um agente terapêutico,composição farmacêutica,e,kit
DK1906916T3 (da) Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
EA202092579A1 (ru) Оксозамещенное соединение
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
AR033151A1 (es) Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
PE20211978A1 (es) Compuesto heterociclo pentaciclico
CO2023014322A2 (es) Terapias de combinación
WO2020128816A3 (en) Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.